On March 31, 2026 Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, reported that the China National Intellectual Property Administration (CNIPA) has granted Chinese Patent, titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The patent, originally filed under PCT Application No. PCT/US2019/048400 and developed by North Carolina State University, strengthens Hoth’s intellectual property portfolio and provides protection in a key global market through August 27, 2039, subject to maintenance requirements.
The granted patent relates to a novel therapeutic platform utilizing splice-switching oligonucleotides designed to selectively induce apoptosis in mast cells, which play a central role in a variety of inflammatory and immunological conditions.
"This patent grant in China represents an important milestone in expanding our global intellectual property protection for this innovative platform," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "We believe this technology has broad potential across multiple indications where mast cell activity contributes to disease, and this issuance further strengthens our position as we advance development."
(Press release, Hoth Therapeutics, MAR 31, 2026, View Source [SID1234664093])